Community Cancer Trials of Utah | Ogden, UT

Research site

(Unclaimed)

Location

5290 S 400 E, Ogden, Utah, United States of America

Site insights

Top conditions

Top treatments

Cyclophosphamide

Prednisone

Bendamustine

Vincristine

Ianalumab

Doxorubicin

Zandelisib

Loperamide

Trastuzumab

Neratinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 28 total trials

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and...

Active, not recruiting

Polycythemia Vera

Drug: Placebo

Drug: Rusfertide

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1)

The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for patients with di...

Active, not recruiting

Diffuse Large B-cell Lymphoma

Drug: Investigator's Choice Chemotherapy

Biological: Epcoritamab

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermed...

Enrolling

Myelofibrosis

Drug: Imetelstat

Drug: Best Available Therapy (BAT)

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis (REFINE)

This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants...

Active, not recruiting

Myelofibrosis (MF)

Drug: Navitoclax

Drug: Ruxolitinib

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids (VAYHIT2)

The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TT...

Enrolling

Primary Immune Thrombocytopenia

Biological: Ianalumab

Drug: Eltrombopag

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer...

Active, not recruiting

Urothelial Cancer

Drug: Erdafitinib

Drug: Docetaxel

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus t...

Active, not recruiting

Breast Cancer

Drug: 5-Fluorouracil

Drug: Cyclophosphamide

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Tepotinib

Drug: Osimertinib

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (OLYMPIA-3)

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study...

Enrolling

Diffuse Large B-cell Lymphoma (DLBCL)

Drug: Doxorubicin

Drug: Prednisone/Prednisolone

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or...

Active, not recruiting

Chronic Lymphocytic Leukemia (CLL)

Drug: Bendamustine

Drug: Rituximab

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling

Small Lymphocytic Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell

Drug: Venetoclax

Drug: Ibrutinib

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma (OLYMPIA-2)

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously u...

Enrolling

Follicular Lymphoma (FL)

Drug: Odronextamab

Drug: Vincristine

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE)

This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding sit...

Active, not recruiting

Chronic Myelogenous Leukemia - Chronic Phase

Drug: asciminib

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their cancer:* cannot b...

Active, not recruiting

Breast Cancer

Drug: Trastuzumab

Drug: Trastuzumab deruxtecan

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTfreedom)

The main purpose of the study was to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients w...

Active, not recruiting

Chronic Myelogenous Leukemia

Drug: Nilotinib followed by treatment-free

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Active, not recruiting

Solid Tumor

Malignant Neoplasm

Drug: nab-sirolimus

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) (VAYHIT1)

The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in m...

Enrolling

Primary Immune Thrombocytopenia (ITP)

Biological: Ianalumab

Drug: Placebo

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or br...

Enrolling

Chemotherapy-induced Thrombocytopenia

Drug: Placebo

Drug: Romiplostim